explore -WSS

explore

author：entertainment 2025-09-30 23:04:29 - browse：693

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

WSS

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

New study raises questions about niacin and heart health

A biotech analyst on neuroscience, placebo effect, not over

Naloxone nonprofit donates 200,000 doses after FDA approval

Wikipedia

explore

focus

New air purifier tech could be key to improving indoor air quality

Drastic changes should bring profitability, startup health insurers say

Affirmative action in medical school literally saved lives

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

What does generative AI mean for health care? We asked experts

New CMS data security rules will hurt Medicare, Medicaid research

Supreme Court strikes down use of affirmative action

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

MD Anderson's Padmanee Sharma responds to research credit suit

Wikipedia

Wegovy’s successful heart trial raises vital question about weight loss

Secretariat’s lessons for human medicine

The best solution to the drug shortages problem

Researchers tackle phage therapy hurdles for wider adoption

Naloxone nonprofit donates 200,000 doses after FDA approval

Elevance, SCAN deals highlight health insurer acquisition scrutiny

focus

Wikipedia

hotspot

hotspot